Kala Pharmaceuticals

OverviewSuggest Edit

Kala Pharmaceuticals is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both the front and back of the eye. It utilizes its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations. The company also researches a small molecule receptor tyrosine kinase inhibitor (RTKi) program as a potential topical treatment of wet age-related macular degeneration (AMD).
TypePublic
Founded2009
HQWatertown, MA, US
Websitekalarx.com
Employee Ratings4.6
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2020)188(+43%)
Revenue (FY, 2015)$45 K
Share Price (Sept 2021)$3(-3%)
Cybersecurity ratingAMore

Key People/Management at Kala Pharmaceuticals

Mark Iwicki

Mark Iwicki

Chairman and Chief Executive Officer
Kim Brazzell

Kim Brazzell

Chief Medical Officer
Hongming Chen

Hongming Chen

Chief Scientific Officer
Mary Reumuth

Mary Reumuth

Chief Financial Officer
Todd Bazemore

Todd Bazemore

Chief Operating Officer
Eric L. Trachtenberg

Eric L. Trachtenberg

General Counsel and Chief Compliance Officer
Show more

Kala Pharmaceuticals Office Locations

Kala Pharmaceuticals has an office in Watertown
Watertown, MA, US (HQ)
490 Arsenal Way, Suite 120
Show all (1)

Kala Pharmaceuticals Financials and Metrics

Kala Pharmaceuticals Revenue

Kala Pharmaceuticals's revenue was reported to be $45 k in FY, 2015
USD

Net income (FY, 2016)

(33.2m)

EBIT (FY, 2016)

(32.7m)

Market capitalization (14-Sept-2021)

197.2m

Closing stock price (14-Sept-2021)

3.0

Cash (31-Dec-2016)

42.5m
Kala Pharmaceuticals's current market capitalization is $197.2 m.
USDFY, 2015FY, 2016

Revenue

45.0k

General and administrative expense

4.6m7.6m

R&D expense

11.4m25.0m

Operating expense total

16.0m32.7m
USDFY, 2015FY, 2016

Cash

5.8m42.5m

Current Assets

7.6m45.6m

PP&E

738.0k594.0k

Total Assets

8.4m46.3m
USDFY, 2015FY, 2016

Net Income

(16.7m)(33.2m)

Depreciation and Amortization

330.0k297.0k

Accounts Payable

911.0(343.0)

Cash From Operating Activities

(15.1m)(27.3m)
Show all financial metrics

Kala Pharmaceuticals Operating Metrics

FY, 2016

Patent Applications

101

Patents (Foreign)

2

Patents (US)

6
Show all operating metrics

Kala Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Kala Pharmaceuticals Online and Social Media Presence

Embed Graph

Kala Pharmaceuticals Company Culture

  • Overall Culture

    A+

    94/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Kala Pharmaceuticals News and Updates

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate …

Thinking about buying stock in Marqeta, Lexicon Pharmaceuticals, Kala Pharmaceuticals, Owlet, or New Oriental Education?

NEW YORK, Aug. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MQ, LXRX, KALA, OWLT, and EDU. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

-- EYSUVIS Prescriptions Increased by 93% Compared to First Quarter of 2021 ---- Further Expanded Commercial Coverage for EYSUVIS to More Than 96 Million Lives ---- Achieved $3.1 Million in Net Revenue in Second Quarter of 2021 ---- Conference Call and Webcast at 8:00 a.m. ET -- WATERTOWN, Mass., Au…

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August

WATERTOWN, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following v…

Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call

WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report second quarter 2021 financial r…
Show more

Kala Pharmaceuticals Blogs

Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx

-- EYSUVIS Added to OptumRx Commercial Formularies Effective May 21, 2021 -- -- Expands Total Commercial Coverage for EYSUVIS to More Than 88 Million Lives -- WATERTOWN, Mass. --(BUSINESS WIRE)--Jun. 3, 2021-- Kala Pharmaceuticals, Inc. , (NASDAQ:KALA), a biopharmaceutical company focused on the

Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference

WATERTOWN, Mass. --(BUSINESS WIRE)--May 27, 2021-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2021 Virtual

Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference

Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference Content Import Thu, 05/06/2021 - 08:01 Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference May 6, 2021 at 8:00 AM EDT This release is a backfill from a News…

Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update Content Import Wed, 05/05/2021 - 07:04 Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update May 5, 2021 at 7:01 AM EDT Th…

Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call

WATERTOWN, Mass. --(BUSINESS WIRE)--Apr. 28, 2021-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2021 financial

Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna

Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna Content Import Tue, 03/16/2021 - 08:01 Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna March 16, 2021 at 8:00 AM EDT This release is a backfill from a News Wire …
Show more

Kala Pharmaceuticals Frequently Asked Questions

  • When was Kala Pharmaceuticals founded?

    Kala Pharmaceuticals was founded in 2009.

  • Who are Kala Pharmaceuticals key executives?

    Kala Pharmaceuticals's key executives are Mark Iwicki, Kim Brazzell and Hongming Chen.

  • How many employees does Kala Pharmaceuticals have?

    Kala Pharmaceuticals has 188 employees.

  • Who are Kala Pharmaceuticals competitors?

    Competitors of Kala Pharmaceuticals include EMS Pharma, Genentech and UCB.

  • Where is Kala Pharmaceuticals headquarters?

    Kala Pharmaceuticals headquarters is located at 490 Arsenal Way, Suite 120, Watertown.

  • Where are Kala Pharmaceuticals offices?

    Kala Pharmaceuticals has an office in Watertown.

  • How many offices does Kala Pharmaceuticals have?

    Kala Pharmaceuticals has 1 office.